The FDA pause on Regenxbio should rattle every AAV gene therapy company

A second pause, a pattern emerging

The FDA has put Regenxbio’s gene therapy for mucopolysaccharidosis type II on hold again. Five patients enrolled in the trial have been found to have small masses on their spines. The company says the patients are not symptomatic. That detail matters, but it may not matter enough.

This comes just seven months after Regenxbio disclosed that a boy treated with its MPS type I therapy — a closely related AAV-based approach — developed a brain tumor. That was the first case conclusively linking an AAV gene therapy to tumor formation. Two separate indications. Two separate safety signals. The same vector platform.

The coincidence is not reassuring to regulators, investors, or the patients waiting on the other side of these trials.

Why AAV is under the microscope

Adeno-associated virus vectors have been the workhorse of gene therapy for roughly two decades. They deliver corrected genes into cells with relative precision and have produced some of the field’s most celebrated successes — Luxturna for inherited blindness, Zolgensma for spinal muscular atrophy, and hemophilia treatments now reaching patients. But AAV carries inherent risks that have become impossible to ignore.

The vector integrates into the host genome at a low frequency, and in rare cases that integration appears to trigger oncogenic events. The brain tumor in the MPS I patient was not a fluke that regulators can file away. It was a warning shot. Now spinal masses in the MPS II cohort suggest the signal may be broader than a single patient’s idiosyncratic response.

The FDA did not say the mass findings were definitively linked to the AAV vector. That ambiguity is both a legal necessity and a strategic choice — the agency knows that premature conclusions could chill an entire class of therapies. But ambiguity is also what keeps a hold in place.

Who loses first

Regenxbio is the most immediate casualty. The company has staked a significant portion of its pipeline on AAV-mediated therapies for lysosomal storage disorders. MPS I and MPS II are adjacent indications with overlapping mechanisms. A hold on one typically casts shadow over the other, even when the data are not identical. Investors will price in the delay before the regulatory briefing does.

But the bigger loss falls on the patients. Hunter syndrome affects roughly one in 100,000 live male births. There is no cure. Enzyme replacement therapy exists but does not cross the blood-brain barrier effectively. Gene therapies like Regenxbio’s are among the few approaches that promise a durable fix. Every month of pause is a month without data, without answers, and without hope for the families enrolled and the families watching from the sidelines.

The broader AAV field also loses. Competing companies developing AAV therapies for neurological and metabolic diseases will face heightened scrutiny. Sponsor interactions with the FDA will grow more cautious. Clinical protocols may require longer follow-up periods and more invasive monitoring — MRI scans of the spine, lumbar punctures, extended imaging protocols — all of which drive up costs and slow enrollment.

What the FDA is signaling

The agency’s posture has shifted visibly since 2023, when the brain tumor case broke. Regulators are no longer treating AAV safety signals as isolated anomalies. They are treating them as early indicators of a class-level risk.

A hold is not a rejection. It is a pause button, and pause buttons can be lifted. But the bar for lifting one has clearly risen. Regenxbio will need to provide more than reassurance — it will need data. Longitudinal imaging showing whether the spinal masses stabilize, regress, or progress. Comparative incidence rates against historical controls. Possibly a dose-response analysis if multiple cohorts exist.

The agency is also sending a message to the wider AAV community: pay attention. Companies in late-stage development with AAV vectors targeting the central nervous system should expect more frequent safety communications and potentially more rigorous pre-study reviews. The era of regulatory deference to AAV is ending.

What comes next

Regenxbio will likely respond with a comprehensive safety update, possibly including independent data monitoring committee review and enhanced imaging protocols for existing patients. The company may also push for a meeting with the FDA to negotiate a path forward rather than wait for the agency to dictate terms.

For the industry, the immediate effect will be slower trial initiations and more conservative dosing strategies. Companies will invest more in preclinical toxicology — longer animal studies, more sensitive tumor markers, better integration-site analysis. The cost of bringing an AAV therapy to market is about to rise, and the timeline is about to lengthen.

Some firms may pivot to non-AAV platforms — lentiviral vectors, episomal approaches, CRISPR-based editing without viral delivery. The switch is expensive and uncertain, but the regulatory pressure makes it increasingly rational.

The patients are still waiting

None of this changes the fundamental reality for children with Hunter syndrome: the disease is progressive, debilitating, and fatal without intervention. Gene therapy offers the best chance. Regulatory caution is necessary, but it is not free. Every additional month of scrutiny extends the gap between what is technically possible and what is actually approved.

The question now is whether the FDA’s caution can coexist with the urgency of rare disease. The agency has the mandate to protect patients from harm. It also has an obligation — implicit, sometimes explicit — to ensure that protection does not become paralysis. How it navigates that tension in the months ahead will define the next cycle of gene therapy development.